IBTIHAL SAUD ALOTAIBI

Motivated allergist dedicated to compassionate, comprehensive care. Expert in diagnosing and treating a range of allergy and immunology conditions, with a special focus on drug allergies. Strong communicator and collaborator, committed to patient well-being. Possesses extensive research experience, contributing to advancements in the field through clinical studies and trials, ensuring innovative and evidence-based treatment approaches.

• 2022: American College of Allergy, Asthma, and Immunology, FIT scholarship award for research presentation at the ACAAI scientific meeting.
• 2021: Certificate of Appreciation from the CEO of the Second health care cluster in the central Region in Riyadh for great efforts and dedicated work in the achievement of the goals of academic affairs department in Al-Yamammah hospital.
• 2012-2013: Awarded second class of Honor Degree from King Saud University.
• 2011-2012: Certificate of Appreciation and gratitude from King Saud University for active participation in improving educational environment in The College of medicine.

• Member of the European Academy of Allergy and Clinical Immunology (EAACI).
• Member of the American Academy of Allergy Asthma and Immunology (AAAAI).
• Member of the American College of Allergy Asthma and Immunology (ACAAI)
• Member of the Saudi Allergy Asthma and Immunology Society.

• 2023-2024: Tolerance of penicillin in patients with confirmed delayed hypersensitivity reactions to aminopenicillins. J Allergy Clin Immunol Pract. 2024 Oct 23:S2213-2198(24)01073-0. doi: 10.1016/j.jaip.2024.10.018. – primary author (poster presented EAACI drug hypersensitivity meeting DHM in Verona, Italy. April 2023)
• 2024: Testing and Challenge in Patients With Immediate Hypersensitivity Reactions to Gadolinium-Based Contrast Agents Identify Safe Future Options. Allergol Int. 2024 Oct;73(4):610-614. doi: 10.1016/j.alit.2024.05.002. Epub 2024 May 30. PMID: 38816288. - Co-author ( published in Allergol Int).
• 2022-2023: REVISITING HYPERSENSITIVITY REACTIONS TO THE MRNA COVID-19 VACCINE: TOLERANCE AFTER PREVIOUS HISTORY OF ANAPHYLAXIS. Ann Allergy Asthma Immunol. 2022 Nov;129(5):S18. doi: 10.1016/j.anai.2022.08.552. Epub 2022 Nov 10. PMCID: PMC9646420– primary author ( abstract presented in ACAAI meeting in Louisville, Kentucky. Awarded FIT awards by ACAAI, puplished in Frontiers in Allergy)
• 2023: COVID-19 booster vaccine acceptance following allergy evaluation in individuals with allergies. J Allergy Clin Immunol Pract. 2024 Jan;12(1):242-245.e2. doi: 10.1016/j.jaip.2023.09.037. Epub 2023 Oct 5. PMID: 37802251. Co-author ( published J Allergy Clin Immunol Pract, Poster Discussion Session with chairs at the DHM in Verona. Italy. April 2023)
• 2023: Utility and Safety of Drug Provocation Testing in Pediatric Ibuprofen Allergy – primary author (presented in drug allergy today session in AAAAI scientific meeting San Antonino, Texas, Feb 2023. Abstract published in the Journnal of Allergy and Clinical Immunology (JACI). Feb 2023) DOI: 10.1016/j.jaci.2022.12.362.
• 2023: The Role Of In vivo and Ex vivo Testing for Delayed Hypersensitivity To Iodinated Contrast Media. Journal of Allergy and Clinical Immunology, Volume 151, Issue 2, AB62. abstract presented at AAAI meeting San Antonino, Texas, Feb 2023 and published in the Journnal of Allergy and Clinical Immunology (JACI). Feb 2023) DOI: 10.1016/j.jaci.2022.12.195
• 2023: Emergency department visits for drug allergy in pediatric population – primary author (ongoing project, under data collection)
• 2023: The impact of challenge testing on the quality of life in adults with suspected drug or food allergies – Coauthor. (Ongoing project, Data collected, manuscript writing).
• 2020: TREC and KREC profiling as Representative of Thymus and Bone Marrow Output in patient with Various Inborn Errors of Immunity. (co-author, published in Journal of Clinical and Experimental Immunology on 26th June 20202).

• 2024: Speaker: Pediatric Update Symposium in the Second Health Care Cluster in Riyadh, Saudi Arabia.
• 2023: Research presenter: Challenging Allergy : Drug Hypersensitivity Symposium 2023 in Melbourne, Australia.
• 2023: Research presenter: American Academy of allergy and Asthma and Immunology annual meeting in San antonio, Texas.
• 2022: Oral abstract presenter: American College of Allergy, Asthma & Immunology (ACAAI) in Louisville, Kentucky.